| | | B. Notwithstanding paragraph A, the department may | | terminate or suspend the participation of a provider in the | MaineCare program in lieu of recoupment pending final | determination regarding an overpayment as long as 30 days' | notice is given pursuant to federal regulation and state | | rule. |
|
| | | Sec. C-7. 22 MRSA §42, sub-§7, ¶H, as amended by PL 2003, c. 613, §2, | | is further amended to read: |
|
| | | H. In an administrative appeal of an informal review | | decision under this subsection, the department bears the | | burden of proving a violation of law or rule by a | | preponderance of the evidence. If the department proves | | that existing and available records of goods or services are | defective, the department may impose a fee penalty or | | sanction, including total recoupment. Total recoupment for | | defective records is warranted only when the provider has | | failed to demonstrate by a preponderance of the evidence | | that the disputed goods or services were medically | | necessary, MaineCare-covered goods or services and were | | actually provided to eligible MaineCare members. |
|
| | | Sec. C-8. 22 MRSA §2698-A, sub-§§3, 4 and 6, as reallocated by RR 2003, | | c. 1, §17 and affected by §18, are amended to read: |
|
| | | 3. Manner of reporting. By July 1st Beginning in 2006, by | | July 1st each year, a manufacturer or labeler of prescription | | drugs that directly or indirectly distributes prescription drugs | | for dispensation to residents of this State shall file a report | | with the department in the form and manner provided by the | | department. The report must be accompanied by payment of a fee, | | as set by the department in rule, to support the work of the | | department under this section. |
|
| | | 4. Content of annual report by manufacturer or labeler. The | | annual report filed under subsection 3 must include the following | | information for each calendar year, beginning with calendar year | | 2005, as it pertains to marketing activities conducted within | | this State in a form that provides the value, nature, purpose and | | recipient of the expense: |
|
| | | A. All expenses associated with advertising, marketing and | | direct promotion of prescription drugs through radio, | | television, magazines, newspapers, direct mail and telephone | | communications as they pertain to residents of this State, | | except for expenses associated with advertising purchased | | for a regional or national market that includes advertising | | within the State; |
|
|